Cliff Asness's BMRN Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 6.69 M shares of BioMarin Pharmaceutical Inc. (BMRN) worth $395.2 M, representing 0.21% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in BMRN, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 2.65 M shares. Largest reduction occurred in Q1 2016, reducing 174,705 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +754,807 | Add 12.72% | 6.69 M | $59.10 |
| Q3 2025 | +351,536 | Add 6.30% | 5.93 M | $54.16 |
| Q2 2025 | +2.65 M | Add 90.74% | 5.58 M | $54.91 |
| Q1 2025 | +1.64 M | Add 127.94% | 2.93 M | $69.72 |
| Q4 2024 | +685,099 | Add 114.47% | 1.28 M | $65.73 |
| Q3 2024 | +543,128 | Add 980.87% | 598,500 | $70.29 |
| Q2 2024 | +32,709 | Add 144.33% | 55,372 | $82.33 |
| Q1 2024 | -34,410 | Reduce 60.29% | 22,663 | $87.34 |
| Q4 2023 | -31,984 | Reduce 35.91% | 57,073 | $96.42 |
| Q3 2023 | -86,329 | Reduce 49.22% | 89,057 | $88.48 |
| Q2 2023 | +99,686 | Add 131.69% | 175,386 | $86.68 |
| Q1 2023 | +25,505 | Add 50.81% | 75,700 | $96.46 |
| Q4 2022 | +21,108 | Add 72.57% | 50,195 | $101.59 |
| Q3 2022 | +21,038 | Add 261.37% | 29,087 | $84.78 |
| Q2 2022 | +1,939 | Add 31.73% | 8,049 | $82.37 |
| Q1 2022 | +3,809 | Add 165.54% | 6,110 | $77.09 |
| Q4 2021 | -1,054 | Reduce 31.42% | 2,301 | $88.22 |
| Q3 2021 | -6,997 | Reduce 67.59% | 3,355 | $77.20 |
| Q2 2021 | +3,001 | Add 40.82% | 10,352 | $83.08 |
| Q1 2021 | -23,264 | Reduce 75.99% | 7,351 | $75.50 |
| Q4 2020 | -76,861 | Reduce 71.51% | 30,615 | $85.84 |
| Q3 2020 | +93,421 | Add 664.68% | 107,476 | $76.08 |
| Q2 2020 | +6,850 | Add 95.07% | 14,055 | $123.23 |
| Q1 2020 | -7,789 | Reduce 51.95% | 7,205 | $82.58 |
| Q4 2019 | +14,994 | New Buy | 14,994 | $84.23 |
| Q4 2016 | -12,718 | Sold Out | 0 | $0.00 |
| Q3 2016 | +12,718 | New Buy | 12,718 | $92.55 |
| Q2 2016 | -10,593 | Sold Out | 0 | $0.00 |
| Q1 2016 | -174,705 | Reduce 94.28% | 10,593 | $82.51 |
| Q4 2015 | -33,306 | Reduce 15.24% | 185,298 | $104.76 |
| Q3 2015 | -92,080 | Reduce 29.64% | 218,604 | $105.32 |
| Q2 2015 | +274,190 | Add 751.33% | 310,684 | $136.78 |
| Q1 2015 | +32,400 | Add 791.40% | 36,494 | $124.62 |
| Q4 2014 | -36,477 | Reduce 89.91% | 4,094 | $90.38 |
| Q3 2014 | -57,300 | Reduce 58.55% | 40,571 | $72.17 |
| Q2 2014 | +73,300 | Add 298.32% | 97,871 | $62.21 |
| Q1 2014 | -55,600 | Reduce 69.35% | 24,571 | $68.21 |
| Q4 2013 | +62,771 | Add 360.75% | 80,171 | $70.27 |
| Q3 2013 | +2,600 | Add 17.57% | 17,400 | $72.24 |
| Q2 2013 | +14,800 | Add 0.00% | 14,800 | $55.81 |
| Q4 2012 | +116,140 | Add 0.00% | 116,140 | $49.25 |
Cliff Asness's BioMarin Pharmaceutical Investment FAQs
Cliff Asness first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q4 2012, acquiring 116,140 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held BioMarin Pharmaceutical Inc. (BMRN) for 42 quarters since Q4 2012.
Cliff Asness's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q2 2025, adding 5,580,573 shares worth $306.43 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 6,686,916 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $395.2 M.
As of the Q4 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.21% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 6,686,916 shares, as reported at the end of Q4 2025.